(Q50896516)

24 March 2018

title

Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia. (English)

1 reference

24 March 2018

0 references

1 reference

1

1 reference

24 March 2018

author name string

J Horácek

2

1 reference

24 March 2018

L Motlová

3

1 reference

24 March 2018

J Libiger

4

1 reference

24 March 2018

P Czobor

5

1 reference

24 March 2018

language of work or name

English

0 references

publication date

1 February 1998

1 reference

24 March 2018

published in

Schizophrenia Research

1 reference

24 March 2018

volume

30

1 reference

24 March 2018

issue

1

1 reference

24 March 2018

page(s)

91-99

1 reference

24 March 2018

Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

The role of serotonin in the pathophysiology and treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Control of prolactin secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

The role of serotonin in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Serotonin, schizophrenia and antipsychotic drug action

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Hormonal responses to d- and d,l-fenfluramine in healthy human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

5-HT2a/2c receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

5-HT3 receptor antagonism by ondansetron does not attenuate prolactin response to d-fenfluramine challenge in healthy human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Dexfenfluramine. An updated review of its therapeutic use in the management of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

From fenfluramine racemate to d-fenfluramine. Specificity and potency of the effects on the serotoninergic system and food intake

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Oral D-fenfluramine and neuroendocrine challenge: problems with the 30 mg dose in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

d- and l-isomers of fenfluramine differ markedly in their interaction with brain serotonin and catecholamines in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Effects of the l isomer of fenfluramine on dopamine mechanisms in rat brain: further studies

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

The role of serotonin in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Effect of pindolol on the prolactin response tod-denfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Increased plasma prolactin levels induced in rats by d-fenfluramine: Relation to central serotonergic stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Prolactin secretion in man: a useful tool to evaluate the activity of drugs on central 5-hydroxytryptaminergic neurones. Studies with fenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Dosage of haloperidol for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Hormonal probes of central serotonergic activity: do they really exist?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Neuroendocrine probes of serotonergic function: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900124-2

7 January 2021

10.1016/S0920-9964(97)00124-2

Identifiers

DOI

1 reference

24 March 2018

1 reference

24 March 2018